Loading…
Can-Fite BioPharma Ltd. is projected to decline to $3.16 by 2027, a -3% move from its current price of $3.25. CANF is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.09 | $3.25 | $3.42 | -0.04% |
| Jul 14 | $3.02 | $3.25 | $3.49 | -0.08% |
| Jul 15 | $2.97 | $3.25 | $3.55 | -0.11% |
| Jul 16 | $2.93 | $3.25 | $3.60 | -0.15% |
| Jul 17 | $2.89 | $3.24 | $3.64 | -0.19% |
| Jul 18 | $2.86 | $3.24 | $3.68 | -0.23% |
| Jul 19 | $2.83 | $3.24 | $3.71 | -0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.83 | $3.24 | $3.71 | -0.27% |
| Week 2 | $2.67 | $3.23 | $3.92 | -0.53% |
| Week 3 | $2.55 | $3.22 | $4.08 | -0.79% |
| Week 4 | $2.45 | $3.22 | $4.22 | -1.06% |
| Week 5 | $2.37 | $3.21 | $4.34 | -1.32% |
| Week 6 | $2.29 | $3.20 | $4.46 | -1.58% |
| Week 7 | $2.23 | $3.19 | $4.57 | -1.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Ramat Gan, Israel. It develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction.
Its pipeline includes Piclidenoson, which has completed Phase III clinical trial for the treatment of psoriasis, and Namodenoson, which is in Phase III for liver cancer, Phase IIa for pancreatic cancer, and Phase IIb for metabolic associated steatohepatitis. CF602 is in pre-clinical trials for erectile dysfunction. The company also offers cannabinoids for treatment of conditions associated with elevated expression of A3 adenosine receptors and a commercial predictive biomarker blood test kit for A3AR.
It has license and collaboration with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd.
in January 2001. It was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
CANF currently trades at $3.48 per share, reflecting a small-cap biotechnology profile with a niche focus in oncology and liver inflammation indications.
Its market capitalization is $7.46M, and its market rank is 5217, placing it among smaller public companies in the market.
The long-range outlook shows potential upside in the coming years, with a 2026 average price of $3.48 and a trajectory that moves toward higher averages by 2030 and beyond, including a 2030 average of $5.58 and a 2050 average of $13.92. The forecast also highlights notable max values and sizable ROIs in later years, underscoring a high-variance, high-uncertainty path typical of clinical-stage biotech names.
A major floor 48.8% below — a decisive break under it would weaken the trend.
The nearest floor, 15.4% below — buyers have tended to step in here.
The nearest ceiling, 42.5% above — a clean break opens room to run.
A major ceiling 85.2% above — clearing it would confirm fresh momentum.
Key CANF support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CANF market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.41 | Sell | $3.36 | Sell |
| MA 10 | $3.42 | Sell | $3.37 | Sell |
| MA 20 | $3.20 | Buy | $3.29 | Sell |
| MA 50 | $3.25 | Buy | $3.29 | Sell |
| MA 100 | $3.44 | Sell | $3.85 | Sell |
| MA 200 | $5.24 | Sell | $6.88 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.64 | Neutral |
| Stoch RSI (14) | 34.50 | Neutral |
| CCI (20) | 10.82 | Neutral |
| Williams %R (14) | -73.40 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 6.56 | Buy |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 26.60 | Neutral |
| TRIX (15) | 0.27 | Buy |
| Awesome (5,34) | 0.21 | Buy |
| Ultimate (7,14,28) | 53.49 | Neutral |
| Momentum (10) | 0.31 | Buy |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 3.18 | Buy |
| ADX (14) | 14.30 | Neutral |
| ATR (14) | 0.20 | Info |
The near-term technical picture is described as bullish. The RSI14 is 50, and the 50-day simple moving average is $3.23 while the 200-day simple moving average is $5.38.
Support and resistance levels are identified at $2.75 and $4.63, respectively. The 30-day price range spans from a low of $2.43 to a high of $4.99, indicating a broad but constructive range in the near term.
Annualized volatility is 100%, signaling substantial price movement potential over time. Near-term dynamics suggest careful monitoring of price action within the established range as news flow and trial updates come in.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.75 | $3.25 | $4.25 | 0% | Neutral | |
| $2.31 | $3.16 | $4.66 | -3% | Neutral | |
| $2.40 | $3.48 | $5.47 | +7% | Neutral | |
| $2.73 | $4.15 | $6.84 | +28% | Bullish | |
| $3.14 | $5.00 | $8.56 | +54% | Bullish | |
| $2.63 | $4.36 | $7.71 | +34% | Bullish | |
| $2.18 | $3.76 | $6.85 | +16% | Neutral | |
| $2.38 | $4.26 | $7.98 | +31% | Bullish | |
| $2.04 | $3.80 | $7.29 | +17% | Neutral | |
| $2.40 | $4.62 | $9.07 | +42% | Bullish | |
| $2.06 | $4.57 | $9.84 | +41% | Bullish | |
| $5.44 | $12.09 | $27.81 | +272% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.75 | $3.25 | $3.73 | +0.00% |
| August 2026 | $2.42 | $2.92 | $3.68 | -10.04% |
| September 2026 | $2.56 | $3.14 | $4.03 | +7.37% |
| October 2026 | $2.61 | $3.23 | $4.22 | +2.93% |
| November 2026 | $2.47 | $3.09 | $4.09 | -4.31% |
| December 2026 | $2.51 | $3.17 | $4.25 | +2.57% |
Click any year to see its month-by-month CANF forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Can-Fite BioPharma Ltd.'s 2026 outlook centres on $3.25, within a $2.75 to $4.25 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CANF could reach as high as $4.66, with a base case around $3.16 and support toward $2.31 — roughly -3% from $3.25. Price action looks broadly range-bound.
Expect CANF to range from $2.40 to $5.47 through 2028. The $3.48 average target implies a +7% move from current prices. That is up +10% on the projected 2027 average. A consolidation phase looks the most probable path here.
The CANF price prediction for 2029 points to an average of $4.15 (low $2.73, high $6.84) — a potential gain of +28% on today's $3.25. Momentum favours further upside here.
In 2030, CANF is projected to trade between $3.14 and $8.56, averaging $5.00 — a potential gain of +54% from today's $3.25. That is up +20% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Can-Fite BioPharma Ltd.'s 2031 outlook centres on $4.36, within a $2.63 to $7.71 range. That is -13% versus the projected 2030 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2032, CANF could reach as high as $6.85, with a base case around $3.76 and support toward $2.18 — roughly +16% from $3.25. A consolidation phase looks the most probable path here.
Expect CANF to range from $2.38 to $7.98 through 2033. The $4.26 average target implies a +31% move from current prices. That is up +13% on the projected 2032 average. Momentum favours further upside here.
The CANF price prediction for 2034 points to an average of $3.80 (low $2.04, high $7.29) — a potential gain of +17% on today's $3.25. A consolidation phase looks the most probable path here.
In 2035, CANF is projected to trade between $2.40 and $9.07, averaging $4.62 — a potential gain of +42% from today's $3.25. That is up +22% on the projected 2034 average. Momentum favours further upside here.
Can-Fite BioPharma Ltd.'s 2040 outlook centres on $4.57, within a $2.06 to $9.84 range. That is -1% versus the projected 2035 average. That marks a +41% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CANF could reach as high as $27.81, with a base case around $12.09 and support toward $5.44 — roughly +272% from $3.25. Momentum favours further upside here.
Investing $1,000 in CANF today (≈ 307.692308 CANF) could be worth
$3,719.84
+$2,719.84 (+272%) by 2050 · US Dollar
Based on the average projected CANF price of $12.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CANFwould be worth at today's price.
$1,000 invested in CANF on Jul 10, 2025 (≈ 48.543688 CANF) would be worth
$157.77
-$842.23 (-84.2%) today · 0.16× · US Dollar
Based on a CANF entry price of $20.6 vs. today's $3.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.91 | $831.2 | -16.9% |
| 1 month ago | $2.82 | $1,152.48 | +15.2% |
| 3 months ago | $2.92 | $1,113.01 | +11.3% |
| 6 months ago | $4.25 | $764.71 | -23.5% |
| 1 year ago | $20.6 | $157.77 | -84.2% |
| All time (5.0y) ago | $446 | $7.29 | -99.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CANF forecast.
Our base-case forecast reaches $6.50 around 2050.
Implied market cap at $6.50: $13.93M
The multi-year forecast shows a bullish trajectory with clear milestones in the 2030 and 2050 horizons. For 2030, the average price is projected at $5.58 with an ROI of 60.4% and a bullish sentiment. By 2040, the average is projected at $4.97 with an ROI of 42.9% and a bullish stance, while 2050 foresees a dramatic rise to an average of $13.92 with an ROI of 300.1% and a bullish tone.
The 2030 forecast includes a min of $3.45 and a max of $9.69, while 2040 shows a min of $2.24 and a max of $10.91. The 2050 forecast projects a min of $6.27 and a max of $32.02. These figures illustrate a wide range of potential outcomes and emphasize the uncertainty inherent in long-horizon biotech equities.
These estimates are not guarantees. Actual results may vary due to a range of factors including clinical trial outcomes, regulatory decisions, market dynamics, and broader financial conditions.
Tap a question to reveal the answer.
The 2026 forecast shows a min of $2.75, an average of $3.48, and a max of $4.62, with an ROI of 0 and neutral sentiment.
Yes: the 2035 forecast lists a min of $2.70, an average of $5.35, and a max of $10.70, with an ROI of 53.9 and bullish sentiment.
$2.43 to $4.99.
Current price is $3.48 and market cap is $7.46M.
The 2050 forecast shows a min of $6.27, an average of $13.92, and a max of $32.02, with an ROI of 300.1 and bullish sentiment.
Can-Fite BioPharma Ltd. Community Discussion
0Share your Can-Fite BioPharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.